It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.03.26.23287767;](https://doi.org/10.1101/2023.03.26.23287767) this version posted March 27, 2023. The copyright holder for this

Abstract

 Background and Aims: Familial hypercholesterolemia (FH) is an autosomal dominant monogenic disease characterized by high low-density lipoprotein cholesterol (LDL-C) levels. Although carrying causative FH variants is associated with coronary heart disease (CHD), it remains unclear whether disclosing its associated cardiovascular risk affects outcomes in patients with FH. Here, we evaluated the efficacy of providing future cardiovascular risk based on genetic testing in addition to a standard FH education program.

- **Methods:** We conducted a randomized, wait-list controlled, open-label, single-center trial. In
- the intervention group, we reported a future cardiovascular risk based on the genetic testing
- adding to standard FH education at week 0. In the wait-list control group, we only disseminated
- standard FH education according to the guidelines at week 0; they later received a genetic
- testing-based cardiovascular risk assessment at week 24. The primary endpoint of this study
- was the plasma LDL-C level at week 24.
- **Results:** Fifty eligible patients with clinically diagnosed FH, without a history of CHD, were
- 46 allocated to the intervention group $(n=24)$ or the wait-list control group $(n=26)$. At week 24,
- the intervention group had a significantly greater reduction in LDL-C levels than the wait-list
- control group (mean changes, -13.1 mg/dL vs. 6.6 mg/dL; difference, -19.7 mg/dL; 95%
- confidence interval, -34 to -5.6; p=0.009)*.* This interventional effect was consistent with FH
- causative variant carriers but not with non-carriers.
- **Conclusions:** In addition to standard FH care, providing future cardiovascular risk based on
- genetic testing can further reduce plasma LDL-C levels, particularly among FH causal variant carriers.
-
- **Registration:** Japan Registry of Clinical Trials (jRCTs04218002).
- URL: https://jrct.niph.go.jp/latest-detail/jRCTs042180027
-
- **Key words:** familial hypercholesterolemia, genetic risk disclosure, genomics, coronary disease,
- randomized clinical trials
-

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Introduction

 Familial hypercholesterolemia (FH) is an autosomal dominant Mendelian disease, one of the leading causes of premature coronary heart disease (CHD) along with life-long exposure 79 to high low-density lipoprotein (LDL) cholesterolemia. $1-6$ The prevalence of patients with heterozygous FH is nearly 0.2-0.5% of the general population (1 in 200-500 individuals). Major FH causative genes are LDL receptor (*LDLR*), proprotein convertase subtilisin/kexin type 9 (*PCSK9*), and apolipoprotein B (*APOB*) and LDLR adaptor protein 1 (*LDLRAP1,* for a particular case of autosomal recessive hypercholesterolemia). FH's clinical guidelines of FH across the world recommend that patients with FH should be treated using lipid-lowering agents at a younger age to reduce plasma LDL cholesterol (LDL-C) levels, which can prevent future episodes of CHD. Therefore, it is important to diagnose FH as early as possible.⁷

 Because FH is a monogenic disorder, genetic testing is important for a definitive 88 diagnosis.⁸ Additionally, our previous study and other studies showed that FH-related 89 pathogenic variants are significantly associated with a higher risk of CHD, $9,10$ which strongly suggests that genetic testing can be used for risk stratification. However, it remains unclear whether FH-related genetic testing would have a potential to affects patients' outcomes beyond risk stratification. Recently, Kullo et al. reported that disclosure of CHD risk estimates with polygenic risk information, which consists of multiple small-effect genome-wide common genetic variations, led to lower LDL-C levels than disclosure of CHD risk based on classical 95 risk factors alone.¹¹ Thus, does providing cardiovascular risk based on FH-related genetic testing also have an impact on changing outcomes in patients with FH?

 Here, we examined whether informing future cardiovascular risk based on genetic testing besides conventional FH patient education leads to reduced LDL-C levels in patients with FH.

Methods

Overall trial design

 This study was a randomized, wait-list controlled, open-label, single-center trial. The detailed trial protocol had been published elsewhere.⁸ In brief, we performed genetic counseling and informed individuals about future cardiovascular risk based on patients' monogenetic testing results for the intervention group. The primary outcome was the change in plasma LDL-C levels at 24 weeks from the baseline. This trial was conducted in compliance with the Declaration of Helsinki, Ethical Guidelines for Medical and Health Research Involving Human Subjects, and all other applicable laws and guidelines in Japan. The study protocol was approved by the Institutional Review Board of Kanazawa University Hospital (Kanazawa, Japan) and registered in the Japan Registry of Clinical Trials (jRCTs042180027).

Participants

 We recruited patients with clinically diagnosed FH from March 2018 to March 2020 and followed them up until October 2021. We enrolled participants who met all the following 116 inclusion criteria: 1) age \geq 15 years; 2) clinically diagnosed with FH according to the Japan 117 Atherosclerosis Society guidelines^{1,9} (if two of the three following criteria were met: [i] LDL- $C \ge 180$ mg/dL, [ii] presence of tendon xanthomas; and [iii] family history of FH or premature coronary artery disease); and 3) never had a genetic test or had not returned genetic results regarding FH. We also excluded participants who met any of the following exclusion criteria: 1) liver dysfunction (aspartate aminotransferase or alanine aminotransferase >3 times the upper 122 normal limits); 2) renal dysfunction (serum creatinine ≥ 2.0 mg/dL); 3) immunosuppressive state; 4) active cancer; 5) history of CHD including myocardial infarction, percutaneous 124 coronary intervention or coronary artery bypass graft, or coronary artery stenosis ($\geq 75\%$) previously detected by coronary angiography; or 6) females expecting to be pregnant or currently pregnant. Written informed consent was obtained from all trial participants.

Screening of FH pathogenic variants

 We sequenced the exons of four FH-related genes (*LDLR*, *PCSK9*, *APOB*, and autosomal recessive inheritance of *LDLRAP1*) using Illumina MiSeq (San Diego, USA). We defined variants as FH causal when they matched any of the following criteria: a) registered as pathogenic/likely pathogenic in the ClinVar database; b) minor allele frequency <1% in the East Asian population with i) protein-truncating variants (nonsense, canonical splice sites, or frameshift) or ii) missense variants with five *in silico* damaging scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, MutationTaster2, LRT), all predicted as pathogenic;¹⁰ c) missense variants reported as pathogenic in the Japanese population: *PCSK9* p.Val4Ile and 137 p.Glu32Lys;^{11,12} and d) predicted by eXome-Hidden Markov Model (XHMM) software as 138 copy number variations (large duplication/large deletion).¹³

Intervention and wait-list control

 We randomized patients to either the intervention or the wait-list control groups with FH using an independent web-based randomization system that included a minimization 143 algorithm balanced for age (>50 years and <50 years), sex (male and female), and causative variant (positive or negative).

 In the intervention group, we performed genetic counseling and informed the patients' future cardiovascular risk based on the results of their FH-related genetic testing in addition to standard FH patient education. The genetic counseling provided by a qualified physician in clinical genetics consisted of the following components: a) genetic diagnosis; b) outline of FH; c) examining the family history of hyperlipidemia/cardiovascular diseases; d) informing that the results of genetic testing could facilitate research in this field; and e) explaining the physical/mental support system in the hospital. In addition, primary cardiologists provided odds ratios of future cardiovascular risk based on the presence or absence of 1) a causal genetic variant and 2) a clinical sign (xanthomas and/or family history of FH) using the original 154 Japanese documents. ^{8,10,14} After counseling, we set sufficient time to answer the questions from the patients, confirming their level of understanding.

 In the wail-list control group, we only disseminated standard FH patient education using 157 the Japanese booklet for FH patient education according to the FH management guideline.¹ After the education session, we set the time to answer the queries from the patients. After 159 evaluating the primary endpoint $(24th$ week after randomization), the wait-list control group also received their genetic testing results and future cardiovascular risks via counseling.

 In both groups, primary cardiologists provided the standard FH education for their patients. Also, primary cardiologists managed LDL cholesterol levels of their patients at their own discretion according to the Japanese guideline for FH 2017 (targeting LDL cholesterol level of <100 mg/dL or >50% reduction compared with an untreated level for primary 165 prevention). ⁹ When adding any of lipid-lowering agents as statins, ezetimibe, or PCSK9 inhibitors, the patients and the physicians must agree with each other for the treatments that were essential to achieve the target value of LDL cholesterol level. Moreover, the number of additional treatments were compared between the intervention and the wait-list control groups. Although in-person FH education was not provided outside of the scheduled outpatient clinic visits, patients in both groups could receive additional counseling and/or outpatient visit when patients wanted or were afraid of genetic testing regardless of the allocated groups during and after the trial.

Outcomes

 The primary outcome was the change in plasma LDL-C levels from baseline (week 0) to week 24. Key secondary outcomes were as follows: 1) changes in plasma LDL-C levels from baseline at week 48 and 2) the Patient Satisfaction Questionnaire Short Form (PSQ-18) scales at weeks 24 and 48. We assessed these outcomes between the intervention and the wait- list control groups or among the four groups categorized by genetic testing results (FH-related causal variant, positive or negative) ([1] intervention + positive; [2] intervention + negative; 181 [3] wait-list control + positive; and [4] wait-list control + negative).

 The PSQ-18 scale evaluates patients' inner satisfaction level for the medical care they 183 received from seven aspects.¹⁵ We used this scale because providing future cardiovascular risk based on genetic testing could create stress for the patients in terms of longer consultation time, higher medical costs, and more drug prescriptions to achieve the target cholesterol level, particularly for the intervention group. The scale values from 1 to 5 represent the lowest to highest rating for each aspect.

 Statistical analysis and early termination due to the coronavirus disease 19 (COVID-19) pandemic

 We hypothesized that the estimated difference from baseline to week 24 in LDL-C levels between the intervention and the wait-list control groups would be 15 mg/dL, with a standard deviation of 25. In the sample size calculation, 44 patients per group were required, with a two-sided α of 5% and power of 80%. We then set the drop-out rate to 10% and 195 determined that approximately 100 patients with FH were required as initially planned.⁸ However, we had to stop the trial enrollment in April 2020 due to the COVID-19 pandemic, with a state of emergency in Japan during the enrollment period. The principal investigator and sub-investigators all agreed to the decision, and we closed the trial in November 2021 after all

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.03.26.23287767;](https://doi.org/10.1101/2023.03.26.23287767) this version posted March 27, 2023. The copyright holder for this

 patients who agreed to enroll in the trial completed the protocol schedule before trial termination.

 We compared the outcomes between the intervention and the wait-list control groups. The baseline profiles were described by mean and standard deviation, median and quantiles (continuous variables), or proportion (categorical variables). In addition, we assessed the primary outcome based on the intention-to-treat approach, which was compared between groups using the *t*-test. Moreover, we compared the secondary endpoints between the groups at each defined period using the *t*-test, Mann-Whitney *U*-test, Fisher's exact test, or linear or logistic regression adjusted for appropriate covariates. A p-value < 0.05 was considered statistically significant for the primary outcome. Statistical analyses were performed using R software version 4.1.2 or above (The R Project for Statistical Computing, Vienna, Austria).

Results

 Figure 1 shows the flowchart of the trial. We recruited 53 clinically diagnosed FH patients without a history of cardiovascular disease from March 2018 to March 2020 and followed them up until October 2021. Of these, three patients were excluded from the trial 215 because of inappropriate eligibility $(n=2)$ and randomization violation $(n=1)$. The remaining $\,$ 50 eligible patients were randomly allocated to the intervention group (n=24) or the wait-list control group (n=26). In the intention-to-treat principle, we included all 50 patients for further 218 analyses. The mean age of the patients was 52 ± 16 years, 58% were female, 22% had hypertension, and 8% had diabetes mellitus. Regarding FH-related profiles, 76% had Achilles tendon xanthomas, 60% reported a family history of FH, and the mean plasma LDL-C level 221 was 127 ± 25 mg/dL. The number of FH-related causative genetic variant positive patients was 34 (68%): 31 patients had causal variants at *LDLR* gene, 1 had causal variant (p.Glu32Lys) at *PCSK9* gene, and 2 had copy number variations at *LDLR* gene. We did not detect any causal

 variants at *APOB* or *LDLRAP1*. The baseline characteristics were well balanced between the intervention and the wait-list control groups (**Table 1**). Since one patient in the wait-list control group refused to follow scheduled visits and laboratory tests after randomization, the study investigators excluded the patient from the study and following outcome analyses.

-
- *Primary outcome*

 At week 24, the intervention group had a significantly greater reduction in plasma LDL- C levels than the wait-list control group (mean changes from baseline, -13.1 mg/dL vs. 6.6 mg/dL; between-group difference, -19.7 mg/dL; 95% confidence interval [CI], -34 to -5.6; p=0.009) (**Table 2, Figure 2**). Even when adjusted by the baseline LDL-C levels, the result was consistent (adjusted difference, -18.0 mg/dL; 95% CI, -32 to -3.8; p=0.02).

Secondary outcomes

 After the wait-list control group also received genetic testing-based future cardiovascular risk assessment at week 24, the LDL-C level in the wait-list control group was certainly decreased (the within-group change from week 24 to 48 was -8.0 mg/dL). In contrast, the within-group change in the intervention group from week 24 to 48 was increased by 4.3 mg/dL, that lead to diminish the effect of LDL-C reduction in the intervention group at week 48 from baseline. As a result, the difference between the two groups (between-group difference) from baseline to week 48 was attenuated (0.7 vs. -2.0; between-group difference, 2.8; 95% CI, -26 to 31; p=0.85) (**Table 2**).

 Figure 3 shows the LDL-C changes according to FH-related causative variant carrier status. Among variant carriers, the intervention group also had a greater plasma LDL-C level 247 reduction than the wait-list control group at week 24 (-19.8 mg/dL vs. 2.9 mg/dL; between-group difference, -22.7 mg/dL; 95% CI, -40 to -5.5; p=0.02). However, we could not detect

 any significant differences between the groups for non-carriers at week 24 (2.3 mg/dL vs. 12.4 250 mg/dL; between-group difference, -10.1 mg/dL; 95% CI, -33 to 12; p=0.39).

 Since the physicians managed LDL cholesterol levels of their patients at their own discretion according to the guideline, we investigated additional treatment regimens on top of the baseline lipid-lowering agents in both groups (**Table 3**). The numbers of participants receiving add-on treatment during the study were 10 (42%) in the intervention group and 6 (23%) in the wait-list control group (chi-square test, p=0.26). Of note, 90% (9/10) in the intervention group and 67% (4/6) in the wait-list control group of add-on lipid-lowering agents were prescribed within 24 weeks from receiving genetic counseling and future cardiovascular risk based on the genetic test. Moreover, the add-on treatments were conducted more frequent in causative variant carrier group (14/16, 88%) than in non-carrier group (2/16, 12%).

Patient satisfaction evaluation

 We further assessed the FH patients' satisfaction for medical care they received during the study period by the PSQ-18 scale analysis (**Figure 4**). We evaluated the score changes by seven aspects (general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience), and there were no between-group differences in each aspect except in the "general satisfaction" aspect for medical care. Notably, FH-related causal variant non-carriers in the intervention group were less satisfied with general medical care than the wait-list control group at 24 weeks.

Subgroup analysis

 Table 4 shows the subgroup analysis results for the treatment differences in LDL-C 272 levels at week 24. There were no significant interactions in each subgroup except that age $(\geq 50$ vs. <50 years) subgroup was the only significant quantitative interaction between the intervention and the wait-list control groups.

Discussion

 This trial was the first randomized, wait-list controlled study to assess whether disclosing the risk for future cardiovascular diseases based on genetic testing results in addition to standard FH education would lead to reduced LDL-C levels in patients with FH. For the primary endpoint, the intervention group showed a significantly greater reduction in plasma LDL-C levels than the wait-list control group at week 24. The difference between the groups was attenuated at week 48 after the wait-list control group also received future cardiovascular risk assessment based on genetic testing at week 24. On the other hand, as for patient satisfaction evaluation by the PSQ-18, no between-group differences were found except for the general satisfaction aspect of medical care. Notably, non-carriers of FH-related causal variants in the intervention group were less satisfied with general medical care than those in the wait-287 list control group at 24 weeks.

 The conclusions of this study are as follows. First, providing cardiovascular risk based on genetic testing further reduced plasma LDL-C levels, in addition to standard FH care. One of the reasons for the significant reduction effect could be that patients with FH may become aware of the necessity of medication, leading to better adherence to medications and achieving lifestyle modifications by themselves. However, there was a concern that the LDL-C reduction might be derived from more intensive treatments based on the information on genetic testing-based cardiovascular risk. Previous studies reported that providing genetic testing results for primary physicians did not affect their practice because they thought plasma lipid levels were simply sufficient to select treatment options for patients with FH and 297 felt little need for genetic testing.^{16,17} Nevertheless, another studies demonstrated that FH

 genetic counseling for patients with FH might convince them of the use of more intensified lipid-lowering drugs and improve medication adherence, leading to lower LDL-C levels, irrespective of their treatment status. ¹⁸⁻²⁰ Moreover, a genetic diagnosis itself could promote the selection of more aggressive lipid-lowering drugs for primary physicians.²¹ For example, the MI-GENES clinical trial, which demonstrated the effect of disclosure of CHD genetic risk on LDL-C levels for patients with intermediate CHD risk, indicated that the lipid-lowering 304 effects were derived from the initiation of statin medication.²² In this study, We did not observe any interactions between baseline plasma LDL-C levels and the addition of lipid- lowering agents between weeks 0 and 24 (**Figure 4**). However, although non-significant, an add-on lipid-lowering treatment was more frequent within 24 weeks from receiving genetic counseling and future cardiovascular risk based on the genetic test (**Table 3**), which might have contributed to the favorable result for LDL-C reduction in the intervention group. In addition, genetic confirmation might help patients with FH reinforce a healthier diet and 311 exercise behaviors.²³ These multilateral effects could affect the LDL-C levels of FH patients without a history of cardiovascular complications. Second, we observed inconsistent effects of the intervention according to the variant

 carrier status on LDL-C levels. For FH-related causal variant carriers, the change in LDL-C levels in the intervention group was greater than that in the wait-list control group at week 24, although this favorable change did not occur in non-carriers. As stated above, providing a

"positive" genetic testing result for patients may improve adherence to lipid-lowering

318 medication and permit access to specific treatments, such as the PCSK9 inhibitor.²⁴

 Moreover, Claassen et al. showed that patients with FH who received their genetic testing 320 results had a higher perceived efficacy of lipid-lowering medication than those without.²⁵ In

contrast, when the FH causal variant was not identified, the negative genetic testing result

322 might provide mental relief even for at-risk patients, ²⁶ which could have a literal "negative"

 effect on non-carrier patients. Additionally, it could cause reduced compliance or motivation 324 in patients.

 Third, although the significant LDL-C reduction was achieved after 24 weeks from the disclosure of future cardiovascular risk based on genetic testing, the effect was attenuated after 48 weeks of the intervention. The changes in LDL-C levels from genetic counseling with providing cardiovascular risk assessment to 24 weeks were consistent in both groups (- 13.1 mg/dL in the intervention group and -8.0 mg/dL in the wait-list control group), whereas the change in LDL-C to 48 weeks was just +0.7 mg/dL despite performing some additional lipid-lowering treatments on the baseline regimen. Although a long-term health behavior 332 change was certainly challenging, $27,28$ our results implicated that the effect of our "one-time" intervention in an outpatient clinic at week 0 might be effective through 6 months but could be attenuated from then on.

 Fourth, genetic counseling for FH did not make patients nervous overall, although non- carriers were less satisfied with general medical care than carriers. In general, patient empowerment is a potential non-clinical benefit of genetic testing. Providing a diagnosis could allow the patient to improve their understanding of the disease's clinical course, treatment 339 options, and psychological control.^{26,29} Genetic testing sometimes ameliorates uncertainty, stigma, and personal guilt.^{30,31} However, it could be valid only in FH patients with positive genetic testing, not in those with negative genetic testing. Patients sometimes undergo genetic testing because they want to confirm whether they are negative. Clinically diagnosed patients with FH are at a higher risk for cardiovascular disease than patients without FH, regardless of the causative variant carrier status. However, when we provide variant-negative patients with less CHD risk than variant-positive FH patients, they might misunderstand the information, become unexpectedly reassured, and decrease their adherence and lifestyle modification. Care might be taken with these "non-carriers" to provide the current FH education strategy with

 future cardiovascular risk assessment based on the variant-negative genetic testing results. This is because the counseling provided in this study might potentially provide misinterpretation and less satisfaction for medical care to "non-carriers". Therefore, alternative counseling strategies may be needed for patients with variant-negative FH.

 The strength of this study was that it was a randomized trial to demonstrate the efficacy of disclosing future cardiovascular disease risk assessment based on genetic testing results in addition to standard FH education for FH patients without a history of cardiovascular disease. The most important limitation of this study was that while we originally planned to enroll 356 approximately 100 FH patients in this study, $8 \text{ we halted enrollment due to the COVID-19}$ pandemic and closed recruitment before completing the pre-specified protocol schedule. Although the effect difference on LDL-C was larger than expected and we demonstrated the efficacy of the intervention on LDL-C levels, this unique situation needs to be considered with caution for clinical application of our findings. In addition, in terms of LDL-C levels, the mean LDL-C levels at 48 weeks were still >100 mg/dL in both groups, which was above the recommended lipid control threshold (<100 mg/dL) for FH patients as primary prevention. Although clarifying cardiovascular risk for both FH patients and primary physicians could 364 improve the treatment quality,³² achieving the target LDL-C level \langle <100 mg/dL) has still been 365 a challenging goal, as the CASCADE-FH registry reported.³³ Although this study's median LDL-C level was lower than that from the registry, we need to focus on the target cholesterol level to reduce the future cardiovascular risk for patients with FH as much as possible. Furthermore, we could not assessed patients' medication adherence except patient-reported drug non-compliance that might affect the results.

 In conclusion, in addition to standard FH care, providing cardiovascular risk assessment based on genetic testing further reduced plasma LDL-C levels further, particularly among

 patients with FH causal variants carriers. Meanwhile, we might be careful with the non-carriers to provide this risk disclosure strategy based on the variant-negative genetic testing results.

Acknowledgements

 We are very thankful to all the participants and staff regarding this trial. We also express our gratitude to Mitsuyo Kusajima, Emi Tamukai, Ryogo Shimizu, Asako Kanadu, and Rika Miyashita as clinical research coordinators; Kenichi Yoshimura, Hideki Ishikawa for randomization and statistical assistance; Yasuhiko Imai, and Jia Yu for clinical data management; and Toshinori Murayama, chairman of the Innovative Clinical Research Center, Kanazawa University for supporting our clinical trial.

Funding

 This trial was supported by a Clinical Research Grant from Kanazawa University Hospital, JSPS KAKENHI (18K08064, 19K08553, 20H03927), the Astellas Foundation for Research on Metabolic Disorders, the ONO Medical Research Foundation, the Ministry of Health, Labour and Welfare of Japan (Research Grant for Rare and Intractable Diseases), and the Japanese Circulation Society (Project for Genome Analysis in Cardiovascular Diseases).

Conflict of interest

The authors have no conflict of interest to disclose.

Data availability statement

 The data in this trial are available from the corresponding author upon reasonable request.

References

- 1. Harada-Shiba M, Arai H, Oikawa S*, et al.* Guidelines for the management of familial hypercholesterolemia. *J Atheroscler Thromb* 2012;**19**:1043-1060. doi:
- 2. Gidding SS, Champagne MA, de Ferranti SD*, et al.* The Agenda for Familial
- Hypercholesterolemia: A Scientific Statement From the American Heart Association.
- *Circulation* 2015;**132**:2167-2192. doi: 10.1161/CIR.0000000000000297
- 3. Watts GF, Gidding S, Wierzbicki AS*, et al.* Integrated guidance on the care of
- familial hypercholesterolaemia from the International FH Foundation. *Int J Cardiol*
- 2014;**171**:309-325. doi: 10.1016/j.ijcard.2013.11.025
- 4. Nordestgaard BG, Chapman MJ, Humphries SE*, et al.* Familial
- hypercholesterolaemia is underdiagnosed and undertreated in the general population:
- guidance for clinicians to prevent coronary heart disease: consensus statement of the
- European Atherosclerosis Society. *Eur Heart J* 2013;**34**:3478-3490a. doi:
- 10.1093/eurheartj/eht273
- 5. Mabuchi H, Nohara A, Noguchi T*, et al.* Molecular genetic epidemiology of
- homozygous familial hypercholesterolemia in the Hokuriku district of Japan. *Atherosclerosis*
- 2011;**214**:404-407. doi: 10.1016/j.atherosclerosis.2010.11.005
- 6. Versmissen J, Oosterveer DM, Yazdanpanah M*, et al.* Efficacy of statins in familial
- hypercholesterolaemia: a long term cohort study. *BMJ* 2008;**337**:a2423. doi:
- 10.1136/bmj.a2423
- 7. Teramoto T, Kobayashi M, Tasaki H*, et al.* Efficacy and Safety of Alirocumab in
- Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High
- Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins-
- ODYSSEY JAPAN Randomized Controlled Trial. *Circ J* 2016;**80**:1980-1987. doi:
- 10.1253/circj.CJ-16-0387
- 8. Nomura A, Tada H, Okada H*, et al.* Impact of genetic testing on low-density
- lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a
- randomised waiting list controlled open-label study protocol. *BMJ Open* 2018;**8**:e023636.
- doi: 10.1136/bmjopen-2018-023636
- 9. Harada-Shiba M, Arai H, Ishigaki Y*, et al.* Guidelines for Diagnosis and Treatment of
- Familial Hypercholesterolemia 2017. *J Atheroscler Thromb* 2018;**25**:751-770. doi:
- 10.5551/jat.CR003

- 10. Khera AV, Won HH, Peloso GM*, et al.* Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *J Am Coll Cardiol* 2016;**67**:2578-2589. doi: 10.1016/j.jacc.2016.03.520 11. Mabuchi H, Nohara A, Noguchi T*, et al.* Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. *Atherosclerosis* 2014;**236**:54-61. doi: 10.1016/j.atherosclerosis.2014.06.005 12. Ohta N, Hori M, Takahashi A*, et al.* Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. *J Clin Lipidol* 2016;**10**:547-555 e545. doi: 10.1016/j.jacl.2015.12.024 13. Fromer M, Moran JL, Chambert K*, et al.* Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. *Am J Hum Genet* 2012;**91**:597- 607. doi: 10.1016/j.ajhg.2012.08.005 14. Tada H, Kawashiri MA, Nohara A*, et al.* Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. *Eur Heart J* 2017. doi: 10.1093/eurheartj/ehx004 15. Marshall G, Hays R. The Patient Satisfaction Questionnaire Short Form (PSQ-18). Santa Monica, CA: RAND Corporation; 1994. p7865. 16. Will CM, Armstrong D, Marteau TM. Genetic unexceptionalism: clinician accounts of genetic testing for familial hypercholesterolaemia. *Soc Sci Med* 2010;**71**:910-917. doi: 10.1016/j.socscimed.2010.05.018 17. Lerner B, Marshall N, Oishi S*, et al.* The value of genetic testing: beyond clinical utility. *Genet Med* 2017;**19**:763-771. doi: 10.1038/gim.2016.186 18. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. *Lancet* 2001;**357**:165-168. doi: 10.1016/S0140-6736(00)03587-X 19. Leren TP. Cascade genetic screening for familial hypercholesterolemia. *Clin Genet* 2004;**66**:483-487. doi: 10.1111/j.1399-0004.2004.00320.x 20. Sturm AC, Knowles JW, Gidding SS*, et al.* Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. *J Am Coll Cardiol* 2018;**72**:662-680.
- doi: 10.1016/j.jacc.2018.05.044

- 21. Paynter NP, Ridker PM, Chasman DI. Are Genetic Tests for Atherosclerosis Ready
- for Routine Clinical Use? *Circ Res* 2016;**118**:607-619. doi:
- 10.1161/CIRCRESAHA.115.306360

22. Kullo IJ, Jouni H, Austin EE*, et al.* Incorporating a Genetic Risk Score Into Coronary

- Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the
- MI-GENES Clinical Trial). *Circulation* 2016;**133**:1181-1188. doi:
- 10.1161/CIRCULATIONAHA.115.020109
- 23. Hagger MS, Hardcastle SJ, Hingley C*, et al.* Predicting Self-Management Behaviors
- in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of
- Beliefs About Illnesses and Beliefs About Behaviors. *Int J Behav Med* 2016;**23**:282-294. doi:
- 10.1007/s12529-015-9531-x
- 24. Brown EE, Sturm AC, Cuchel M*, et al.* Genetic testing in dyslipidemia: A scientific
- statement from the National Lipid Association. *J Clin Lipidol* 2020;**14**:398-413. doi:
- 10.1016/j.jacl.2020.04.011
- 25. Claassen L, Henneman L, van der Weijden T, Marteau TM, Timmermans DR. Being
- at risk for cardiovascular disease: perceptions and preventive behavior in people with and
- without a known genetic predisposition. *Psychol Health Med* 2012;**17**:511-521. doi:
- 10.1080/13548506.2011.644246
- 26. Severin F, Borry P, Cornel MC*, et al.* Points to consider for prioritizing clinical
- genetic testing services: a European consensus process oriented at accountability for reasonableness. *Eur J Hum Genet* 2015;**23**:729-735. doi: 10.1038/ejhg.2014.190
- 27. Middleton KR, Anton SD, Perri MG. Long-Term Adherence to Health Behavior Change. *Am J Lifestyle Med* 2013;**7**:395-404. doi: 10.1177/1559827613488867
- 28. Bouton ME. Why behavior change is difficult to sustain. *Prev Med* 2014;**68**:29-36.
- doi: 10.1016/j.ypmed.2014.06.010
- 29. Berberich AJ, Hegele RA. The role of genetic testing in dyslipidaemia. *Pathology* 2019;**51**:184-192. doi: 10.1016/j.pathol.2018.10.014
- 30. Senior V, Smith JA, Michie S, Marteau TM. Making sense of risk: an interpretative
- phenomenological analysis of vulnerability to heart disease. *J Health Psychol* 2002;**7**:157-
- 168. doi: 10.1177/1359105302007002455
- 31. Weiner K, Durrington PN. Patients' understandings and experiences of familial
- hypercholesterolemia. *Community Genet* 2008;**11**:273-282. doi: 10.1159/000121398

- 32. Jones LK, Sturm AC, Seaton TL*, et al.* Barriers, facilitators, and solutions to familial
- hypercholesterolemia treatment. *PLoS One* 2020;**15**:e0244193. doi:
- 10.1371/journal.pone.0244193
- 33. deGoma EM, Ahmad ZS, O'Brien EC*, et al.* Treatment Gaps in Adults With
- Heterozygous Familial Hypercholesterolemia in the United States: Data From the
- CASCADE-FH Registry. *Circ Cardiovasc Genet* 2016;**9**:240-249. doi:
- 10.1161/CIRCGENETICS.116.001381
-

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.03.26.23287767;](https://doi.org/10.1101/2023.03.26.23287767) this version posted March 27, 2023. The copyright holder for this

Figure legends.

Figure 1. Trial flowchart.

We enrolled 53 patients with clinically diagnosed FH and no prior coronary artery disease. Of

those, 50 eligible FH patients were randomly allocated to the intervention group (24 patients

receiving conventional FH education and future cardiovascular risk assessment based on

genetic testing) or the wait-list control group (26 patients receiving only conventional FH

education). We followed the two groups for up to 48 weeks and performed an intention-to-

treat analysis. The primary endpoint was the change in LDL-C levels from baseline at week

24. Because we handled the wait-list control group as a wait-list group, we also provided

future cardiovascular risk assessment based on genetic testing after evaluating the primary

- endpoint at week 24.
-

Figure 2. Low-density lipoprotein cholesterol changes from baseline.

Regarding the primary endpoint at week 24, the intervention group had a significantly greater

reduction in plasma LDL-C level than the wait-list control group. After the wait-list control

group also received genetic testing-based future cardiovascular risk assessment at week 24,

516 the difference between the two groups was attenuated at week 48. *:p<0.05. Error bars

- indicated the standard error.
-

Figure 3. Low-density lipoprotein cholesterol changes from baseline by FH-related causative variant carrier status with additional treatment information.

 A. Variant carriers (n=34). **B.** Non-carriers (n=16). Treatment icons (statin or ezetimibe, statin and ezetimibe, or PCSK9 inhibitor) were placed at the time of each additional medication. Among variant carriers, the intervention group also had a greater plasma LDL-C level reduction than the wait-list control group at week 24. However, we could not detect any apparent differences between the groups for non-carriers. Error bars indicated standard errors

Figure 4. Changes in patient satisfaction questionnaire scale scores by groups.

 There were no between-group differences except in the "general satisfaction" aspect of medical care. According to the general satisfaction scale results, variant non-carriers in the intervention group were less satisfied with general medical care than the wait-list control group at 24 weeks. *:p<0.05. Error bars indicated the standard error.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

532 **Table 1.** Baseline characteristics.

- Continuous values were expressed as mean ± standard deviation or median (interquartile range).
- Abbreviations: AR, autosomal recessive; BMI, body mass index; bpm, beats per minutes; FH,
- familial hypercholesterolemia; LDLR, low-density lipoprotein receptor; PCSK9, proprotein
- convertase subtilisin/kexin type 9; PSQ-18, Patient Satisfaction Questionnaire Short Form.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

538 **Table 2. Within-group changes and between-group differences of LDL cholesterol**

539 **levels.**

540

541 *:P values were calculated comparing the intervention group with the wait-list control group

542 using the *t*-test. **: p<0.05.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

544 **Table 3. Add-on treatment regimens by primary physicians during study period.**

545

546 PCSK9, proprotein convertase subtilisin/kexin type 9.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

547 **Table 4.** Treatment differences in low-density lipoprotein cholesterol changes at week 24

548 between the intervention and the wait-list control groups by patient subgroups.

549

550 Abbreviations: BMI, body mass index; CI, confidence interval; FH, familial 551 hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

552 **Figure 1.** Trial flowchart.

553

- 557 **Figure 3.** Low-density lipoprotein cholesterol changes from baseline by FH-related causative
- 558 variant carrier status with additional treatment information.

Figure 4. Changes in patient satisfaction questionnaire scale scores by groups.